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Abstract The actions of glucagon-Uke peptide-l(7-36)amide 
(GLP-1 (7-36)amide) on cellular signalling were studied in human 
embryonal kidney 293 (HEK 293) cells stably transfected with the 
cloned human GLP-1 receptor. The cloned GLP-1 receptor 
showed a single high-affinity binding site (Kd = 0.76 riM). Binding 
of GLP-l(7-36)amide stimulated cAMP production in a dose- 
dependent manner (ECs0 = 0.015 nM) and caused an increase in 
the intracellular free Ca 2+ concentration ([Ca2+]i). The latter ef- 
fect reflected Ca2+-induced Ca 2+ release and was suppressed by 
ryanodine. We propose that the ability of GLP-l(7-36)amide to 
increase [Ca2+]i results from sensitization of the ryanodine recep- 
tors by a protein kinase A dependent mechanism. 
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I. Introduction 
Glucagon-like peptide l (GLP-1) is a gastrointestinal 
hormone with potent insulinotropic effects on the endocrine 
pancreas. GLP-1 mediates its effects by binding to specific 
receptors on the pancreatic fl-cells thereby stimulating cAMP 
formation and insulin secretion [1,2]. Ca 2+ plays a central role 
in the stimulus-secretion coupling, and a GLP- l -evoked in- 
crease in the intracellular free calcium concentration ([Ca2+]i) 
is one of the decisive events leading to an insulin secretory 
response in the fl-cell. We have previously demonstrated that 
in the mouse insulin-secreting cell line ffI'C3, GLP- l (7-  
36)amide produces a rise in [Ca2+]~ by promoting Ca2+-induced 
Ca2+-release (CICR) from intracellular stores [3]. The recent 
cloning of the GLP-1 receptor [4,5] has enabled a more detailed 
analysis of the cellular processes involved. Here we demon- 
strate for the first time that expression of the cloned GLP-I  
receptor in HEK 293 cells is associated with the induction of 
later steps in the sequence of events normally activated by 
GLP-1. These events include generation of cAMP and mobili- 
zation of Ca 2+ from intracellular stores by ryanodine-sensitive 
CICR. 
2. Materials and methods 
2.1. Reagents 
Rp-cAMPS was obtained from BIOLOG Life Science Institute (Bre- 
men, Germany). Fura-2 acetoxymethyl ester (fura-2/AM), fura-2 pen- 
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tapotassium salt, and BAPTA/AM were supplied by Molecular Probes 
(Eugene, OR, USA). EGTA was from Fluka (Buchs, Switzerland). 
Ryanodine was obtained from Alomone Labs (Jerusalem, Israel). 
U73122 was from Biomol (Plumouth Meeting, PA, USA). Ionomycin 
was provided by Calbiochem (La Jolla, CA, USA). Dulbecco's modi- 
fied eagle medium (DMEM), Hanks' balanced salt solution (HBSS), 
trypsin, and Lipofectin transfection reagent were from Gibco BRL, 
(Life Technologies, Inc, MD, USA). Synthetic GLP-l(7-36)amide was 
synthesized as described elsewhere [61. [125I]GLP-1 (7-36)amide was pre- 
pared by iodinating the peptide with ~25I using HzO2/lactoperoxidase at 
neutral pH and purified by reverse-phase HPLC as described elsewhere 
[7], resulting in a specific activity of 1.76/.tCi/pmol. All other chemicals 
were obtained from Sigma Chemicals (St. Loius, MO, USA). 
2.2. Expression of the cloned human GLP-1 receptor 
The human GLP-1 receptor cDNA was obtained from Dr. B. 
Thorens (Department of Pharmacology and Toxicology, University of 
Lausanne, Switzerland). The cDNA was subcloned as a EcoRI frag- 
ment into EcoRI cut pcDNA3 (expression vector from Invitrogen 
Corp. San Diego, CA, USA) resulting in pBW302. HEK 293 cells were 
transfected with 2 pg pBW302 by lipofection using Lipofectin accord- 
ing to the manufacturer's in tructions. The cells were grown at 5% CO2 
in DMEM supplemented with 10% fetal calf serum, 50 IU pencillin, 50 
pg/ml streptomycin, and 1% non-essential mino acids. Stable clones 
were selected in culture medium containing 1mg/ml reagent G418. All 
data shown in the present study were obtained from one clone with a 
GLP-I receptor expression level of 850 fmol/mg protein (i.e. approx. 
150000 receptors/cell). 
2.3. Receptor binding assay 
Receptor binding was analyzed using membranes from HEK 293 
cells. Batches of cells were harvested and homogenized with short 
bursts using an Ultra-turrax T25 homogenizer (Janke and Kunkel, 
Germany) in a buffer containing (in mM): 25 HEPES, 2.5 CaCI2, 
1 MgCI2 and 50 mg/1 Bacitracin (pH 7.4). The membranes were centri- 
fuged at 48000 × g and the supernatant was discarded. After resuspen- 
sion in 5 ml buffer, the pellet was homogenized again and the above 
steps repeated once. The protein concentration was adjusted to 75 
/tg/ml and bovine serum albumine (fraction V) was added to a final 
concentration of 0.1% w/v. Aliquots of 500 pl membranes were incu- 
bated with 25/ll [~25I]GLP-l(7-36)amide (105 cpm) and 25 ~1 of GLP- 
l(7-36)amide and incubated for 60 rain at 37°C. Bound and unbound 
peptide was separated by filtration through Whatman GF/C 3607 filters 
preincubated in 0. 1% polyethylenimin. After filtration, the filters were 
counted for radioactivity in a gamma scintillation counter. 
2.4. Measurements ofcAMP levels 
Intracellular cAMP levels were measured in HEK 293 cells grown to 
approximately 70% confluency in Nunc 24-well multidishes (1ml). The 
cells were first incubated for 15 rain in the presence of 1 mM of the 
phospbodiesterase inhibitor IBMX and subsequently stimulated with 
GLP- 1 (7-36)amide for 15 rain in the continued presence of IBMX. The 
reaction was terminated by the addition of HC1 to a final concentration 
of 50 mM. The samples were neutralized with 50 mM NaOH and 
assayed for cAMP using a cAMP [z25I] scintillation proximity assay 
(RPA 542; Amersham, UK). 
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2.5. Measurements of [Cd+]i 
Images of [Ca2+]i in single HEK 293 ceils were obtained using an 
inverted fluorescence microscope (Zeiss Axiovert 135; Oberkochen, 
Germany) and an Image-1 (Universal Imaging, West Chester, PA, 
USA) image processing system, as described elsewhere [3]. The cells 
were loaded with 3 pM fura-2/AM for 30 min at 37°C followed by 
washing and resuspension i  extracellular solution containing (in mM) 
140 NaC1, 4 KC1, 2 CaCI2, 1 MgCI2, 10 HEPES, pH 7.3 (NaOH). The 
Ca2+-free medium was without added Ca 2÷ and supplemented with 100 
,uM EGTA. [Ca2+]i was calculated from the measurements of the ratio 
of fluorescence intensities according to [8]: [Ca2+]i = Kd'[(R - Rmln)/ 
(Rmax-R)].(Sf2/Sb2). The pixel gray values for Rmax were 
obtained using ionomycin (1/~M) and was determined as 238. Rm~, and 
the proportionality constant (S~/Sbz) were 27 and 9.8, respectively. A
value for the apparent Kd of Ca z+ binding to fura-2 of 224 nM was used 
[S]. 
2.6. Statistical analysis 
All data are expressed as mean values + S.E.M. for n tested cells/ 
experiments. 
3.  Resu l t s  and  d i scuss ion  
3.1. GLP-1 receptor binding and cAMP formation 
To ensure that the transfected HEK 293 cells express the 
human GLP-1 receptor, binding analysis was performed with 
GLP-l(7-36)amide. In HEK 293 cells stably transfected with 
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Fig. 1. (A) Displacement of [125I]GLP-l(7-36)amide binding to HEK 
293 cells expressing the cloned human GLP-I receptor by GLP- I (~ 
36)amide. (B) GLP-l(%36)amide-evoked cAMP production assessed 
in intact cells in the presence of 1 mM of the phosphodiesterase inhib- 
itor IBMX. 
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Fig. 2. GLP-l(7-36)amide-evoked changes in [Ca2+]i in HEK 293 cells 
expressing the cloned human GLP-I receptor. (A) HEK 293 cells were 
stimulated with 10 nM GLP-l(7-36)amide in a Ca 2÷ containing (A) or 
a Ca2+-free medium with 100 tIM EGTA (B). The cells were subse- 
quently stimulated with 10/IM ACh. The traces are representative of 
53 and 68 cells from 6 and 8 different experiments. 
the GLP-1 receptor specific binding of ~25I-labelled GLP- l (7 -  
36)amide was displaced in a concentration-dependent manner 
using unlabelled GLP-l(7-36)amide. As illustrated in Fig. 1A, 
the binding data are consistent with the presence of a single 
high-affinity binding site with K a of 0.76 + 0.14 nM (n = 9). 
Fig. 1B demonstrates that the cloned GLP-1 receptors asso- 
ciate with endogenous adenylate cyclase as indicated by meas- 
urements of GLP-l(7-36)amide-induced cAMP formation in 
intact HEK 293 cells. GLP-l(7-36)amide stimulated cAMP 
production in a concentration-dependent manner with half- 
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Fig. 3. GLP-l(7-36)amide stimulates Ca2+-induced Ca2+-release by a cAMP-dependent mechanism in HEK 293 cells. (A) 100 ~tM ryanodine was 
added to the extracellular medium 3 min before stimulation with 10 nM GLP-l(7-36)amide and subsequently with 10/IM ACh. (B) the cells were 
exposed to 10 pM of the phospholipase C inhibitor U73122 for 5 min before stimulation with 10 nM GLP-l(7-36)amide followed by 10 pM ACh. 
(C) The specific PKA inhibitor Rp-cAMPS (15/.tM) was added 5 rain before stimulation with 10 nM GLP-l(7-36)amide and 10 pM ACh. (D) 
Summerizes the average changes in [Ca2*]~ under the different experimental conditions. The traces are representative of 23-34 cells from 4 to 7 
individual experiments. 
maximal effect being observed at 14.9 + 0.4 pM (n = 6). Similar 
results for receptor binding and cAMP formation were ob- 
tained using GLP-1(7-37) or exendin-4. In 'wild type' HEK 293 
cells or in cells transfected with the pcDNA3 vector neither 
GLP-l(7-36)amide binding nor GLP-l(7-36)amide-induced 
cAMP production was observed (not shown). The data summa- 
rized in Fig. 1 are similar to those previously reported for the 
cloned rat and human GLP-1 receptor in stably transfected 
fibroblasts [5,9] and for the endogenoes receptor expressed in 
insulinoma cell lines [4,9] but lower than those reported for 
transiently transfected COS-7 cells [10,11]. 
3.2. The GLP-1 receptor causes mobilization of Ca e÷ from 
intracellular stores 
Fig. 2A shows that stimulation of HEK 293 cells expressing 
the GLP-1 receptor by 10 nM GLP-l(7-36)amide results in a 
rapid increase in [Ca2+]i from a resting value of 97 + 12 nM 
(n = 178) to approximately 650 nM which was followed by a 
gradual return to the prestimulatory level within 5-6 min de- 
spite the continued presence of the agonist. Subsequent s imu- 
lation with ACh (10/IM) caused an increase in [Ca2*]i of the 
same amplitude as that observed following stimulation with 10 
nM GLP-l(7-36)amide. These effects of GLP-l(7-36)amide 
and ACh reflect largely mobilization of intracellular Ca 2+ 
rather than stimulation of its influx because qualitatively simi- 
lar responses to the agonists were obtained in the absence of 
extracellular Ca 2+ (Fig. 2B). It is generally believed that the 
effect of GLP-1 in various tissues involves the activation of a 
G-protein [2]. This also appears to be the case in the transfected 
HEK 293 cells and pretreatment of the cells with 100 ng/ml 
pertussis toxin for 24 h reduced the [Ca2+]i-increasing action of 
GLP-l(7-36)amide by 74 + 3% (n = 26) whilst not affecting the 
effect of ACh (not shown). 
3.3. GLP-1 (7-36)amide stimulates Cd+-induced Ca e+ release 
Whereas ACh strongly stimulated the generation of 
Ins(1,4,5)P 3 and its degradation products, as determined by 
HPLC separation, 10 nM GLP-l(7-36)amide had no effect on 
the concentrations of the inositol phosphates (data not shown). 
We conclude therefore that the ability of GLP-1 (7-36)amide to 
mobilize intracellular Ca 2÷ in HEK 293 cells transfected with 
the human GLP-1 receptor takes place via a mechanism inde- 
pendent of the phospholipase C/Ins(1,4,5)P 3 pathway. 
We have previously proposed that the capacity of GLP-1 to 
increase [Ca2+]i in flTC3 insulinoma cells involves the activation 
of CICR [3]. We next went on to investigate whether the same 
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Fig. 4. Elevation of [Ca2+]~ stimulates Ca:+-induced Ca 2÷ release at 
subthreshold GLP-l(7-36)amide concentrations. (A) stimulation of 
HEK 293 cells with GLP-l(7-36)amide (0.1 nM) does not evoke 
changes in [Ca2÷]~. Subsequent addition of ionomycin causes aslow rise 
in [Ca2+]i which triggers arapid rise in [Ca2+]i. This latter Ca:* response 
is not observed in cells pretreated for 5 min with 100/~M ryanodine (B) 
or with 15 pM Rp-cAMPS (C). The traces are represensative of 34~41 
cells from (~8 individual experiments. 
mechanism becomes operational in HEK 293 cells transfected 
with the human GLP-1 receptors. As shown in Fig. 3A this is 
likely to be the case as the ability of GLP-1 (7-36)amide, but not 
ACh, to increase [Ca2+]i in these cells was abolished by ryan- 
odine (100/aM), a potent inhibitor of CICR [12]. By contrast, 
inclusion of 10/aM U73122, an inhibitor of phospholipase C 
(PLC)-mediated processes [13,14] selectively inhibited the ACh- 
evoked [Ca2+]i response whilst not affecting the response to 
GLP-l(7-36)amide (Fig. 3B,D). Finally, inhibition of protein 
kinase A (PKA) by pretreatment of the cells with Rp-cAMPS 
[15] suppressed the GLP-l(7-36)amide-evoked rise in [Ca2+]i 
but did not affect the amplitude of the ACh-induced [Ca2+]~ 
response (Fig. 3C,D). 
3.4. GLP- l  ( 7-36)amide sensitizes Ca2+-induced Ca 2+ release 
channels 
The above results uggest that GLP-l(7-36)amide promotes 
Ca 2+ mobilization from intracellular stores through activation 
of ryanodine sensitive Ca 2÷ release channels. We next investi- 
gated whether this PKA-mediated Ca2+-release process results 
from sensitization of the intracellular Ca 2+ release channels to 
resting [Ca2+]i. Fig. 4A shows an experiment where a HEK 293 
cell was stimulated with 0.1 nM GLP-l(7-36)amide, a concen- 
tration which in itself is insufficient to cause a rise in [Ca2+]~. 
Subsequent addition of a low concentration (10 nM) of the Ca 2+ 
ionophore ionomycin induced a slow gradual increase in [Ca2÷]i 
which triggered a rapid and transient further elevation of [Ca2+]i 
which is abolished by pretreatment of the cells with either 
ryanodine or Rp-cAMPS (Fig. 4B,C). 
3.5. Conclusions 
Expression of the cloned human GLP-1 receptor in HEK 293 
not only results in the appearance of GLP-l(7-36)amide bind- 
ing sites with properties indistinguishable from those of the 
native receptors. More importantly, the insertion of these re- 
ceptors in the HEK 293 cells also leads to the activation of more 
distal steps in the signal transduction pathway utilized by GLP- 
1. For example, there is a GLP-l-dependent production of 
cyclic AMP and mobilization of intracellular Ca 2+ from ryan- 
odine-sensitive intracellular Ca2+-stores. The effects of GLP- 
l(7-36)amide on [Ca2+]i-handling in HEK 293 cells expressing 
the cloned GLP-1 receptor are remarkably similar to those 
previously reported by us and others in insulin-secreting-cells 
[3,16]. This suggests that cAMP-dependent modulation of the 
ryanodine receptors (and Ca2+-release channels) may represent 
a fundamental cellular property which links receptor activa- 
tion, via stimulation of adenylate cyclase, to an increase in 
[Ca2+]~ which in turn accounts for the cellular esponses. In this 
context it is pertinent that all ryanodine receptor isoforms con- 
tains PKA consensus phosphorylation sites [17]. The observa- 
tion that the GLP-I(7 36)amide-evoked Ca2+-response is
blocked by Rp-cAMPS finally excludes the possibility that 
cADP-ribose, a newly discovered Ca 2÷ mobilizing nucleotide of 
NAD ÷ [18,19] is responsible for the observed [Ca2+]i responses 
following GLP-I(7 36)amide stimulation. 
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